ShRNA apolipoprotein B100 gene siliencer (Amsterdam Molecular Therapeutics)

N/A

Report date: 2024/09/02 15:51:59

Base Information

Drug NameShRNA apolipoprotein B100 gene siliencer (Amsterdam Molecular Therapeutics)
Drug Alias NameApoB100 gene therapy (uniQure)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > short hairpin RNA
Mechanisms of ActionApolipoprotein B-100 modulators
TargetsApolipoprotein B-100
Therapy Area/IndicationsHypercholesterolemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAmsterdam Molecular Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAmsterdam Molecular Therapeutics
Active IndicationsN/A
Inactive IndicationsHypercholesterolemia

Other Information

ATC CodeN/A
Related LinksN/A